Many women notice it a year or two after their last period: a parting that looks a little wider, a ponytail that feels a little thinner, more scalp showing under the bathroom light. It is easy to shrug and call it ageing. But the science says something more specific is going on at the hair follicle, and that matters, because it changes what can be done about it.

Myth: "My Hair Is Thinning Because I'm Getting Older"

Age does play a part. Hair follicles slowly produce finer strands over the decades. But the thinning many women see after menopause usually has a distinct pattern: it concentrates on the crown and along the parting, while the front hairline tends to hold. Dermatologists call this female pattern hair loss, and it is driven as much by hormones as by birthdays.

Science: The Hormone Balance at the Follicle Shifts

Think of estrogen as a protective buffer for your hair. During the reproductive years it helps keep follicles in their growth (anagen) phase for longer. At menopause, that buffer drops away.

• Androgens take a bigger role: Women still make androgens (male-type hormones). With less estrogen to balance them, their influence on the follicle grows, even if blood levels look normal.
• DHT is the key messenger: An enzyme called 5-alpha-reductase converts testosterone into dihydrotestosterone (DHT) right inside the scalp. In genetically sensitive follicles, DHT gradually shortens the growth phase.
• Miniaturisation: Over successive cycles, affected follicles shrink and produce shorter, finer, lighter hairs. The number of follicles may stay the same, but the hair they grow covers less scalp.

This is why hormone-aware treatments are being studied specifically for women after menopause.

Where Finasteride Comes In

Finasteride blocks type II 5-alpha-reductase, lowering DHT at the source. It is best known as a tablet for male pattern hair loss, which we covered in Understanding Finasteride: A Guide to Oral Consumption for Hair Loss. In women, its use is off-label and must be guided by a doctor.

The evidence in women has been mixed. An early study found that 1 mg oral finasteride did not help postmenopausal women with pattern hair loss, while later studies using higher doses reported better results. That uncertainty is one reason researchers have turned to a topical version: a solution sprayed onto the scalp, designed to act where it is needed while keeping whole-body exposure lower.

What the New 52-Week Study Adds

In October 2026, the International Journal of Dermatology published a 52-week retrospective study of topical finasteride 0.25% solution in postmenopausal women with female pattern hair loss. A full year of follow-up matters, because hair grows slowly and most treatments need six to twelve months to show what they can do.

It builds on earlier work. A 2024 retrospective study of 120 postmenopausal women compared topical finasteride, oral finasteride and topical minoxidil over 12 months. In the topical finasteride group, 24 of 40 women showed moderate or significant improvement in hair density, and side effects were mild (three reported itching). The differences between the three treatments were not statistically significant, so the authors called for proper randomised trials.

• What these studies can tell us: topical finasteride appears tolerable and may help some women over a year.
• What they cannot tell us: both are retrospective, without a placebo group, so they show association rather than proof.

Important Safety Points

• Never during possible pregnancy: finasteride can affect the development of a male foetus. It is not for anyone who is or could become pregnant, which is why studies focus on women after menopause.
• Mood: low mood and depression have been reported with finasteride, and a public health essay published the same week argued that regulators should take this more seriously. Tell your doctor about any history of depression, and report changes in mood promptly.
• No self-sourcing: avoid buying compounded solutions online. Concentration, purity and dosing matter.

The Other Side of the Follicle: Energy

Hormones are one half of the story. The other is energy. Hair follicles are among the most active cells in the body, and the growth phase depends on a steady supply of cellular fuel (ATP) from the mitochondria.

This is where low-level laser therapy (LLLT) works. Red light at around 650–680 nm is absorbed by an enzyme in the mitochondria, supporting energy production in the follicle. It does not touch hormones at all, which is why it is often discussed as a complement to medical treatments rather than a replacement.

The most relevant evidence in women comes from a 2024 randomised trial: women using 2% minoxidil plus a 655 nm laser helmet had a significantly greater increase in hair thickness on the mid-scalp (14.7% versus 1.4%) than those using minoxidil alone. No trial has yet tested laser therapy alongside topical finasteride specifically, but because the two work on different pathways, they can sit together in one doctor-guided plan.

Tip: At-home helmets such as the FDA-cleared Theradome bring laser sessions into your routine without clinic visits. Read how they compare in Do You Really Need a Clinic Visit for Laser Hair Growth, or Will a Helmet Do.

Building a Plan After Menopause

• Get checked first: ask your doctor about iron (ferritin), thyroid function and vitamin D, as deficiencies can mimic or worsen pattern thinning.
• Hormone side: discuss medical options such as minoxidil, topical finasteride or other anti-androgens with a dermatologist. See our deep dive on minoxidil.
• Energy side: consistent low-level laser therapy at home.
• Nutrition: adequate protein is the raw material for keratin. Our guide to protein for strong hair has practical targets.
• Track progress: take photos of your parting every month in the same light. Changes are slow, and photos show what the mirror misses.

Key Takeaway

Hair thinning after menopause is not just ageing. It reflects a real shift in the hormone balance at the follicle, and that opens the door to targeted care. A new year-long study adds to the case for topical finasteride as a doctor-led option for women after menopause, while low-level laser therapy works on the follicle's energy supply. Two pathways, one plan, guided by your doctor and given the time hair needs.

This article is for general education and is not medical advice.

References

• Topical finasteride 0.25% solution for female pattern hair loss in postmenopausal women: a 52-week study. International Journal of Dermatology. 2026 (online 15 Oct). PubMed 42876360
• Starace MVR, Gupta AK, Bamimore MA, et al. The comparative effects of monotherapy with topical minoxidil, oral finasteride, and topical finasteride in postmenopausal women with pattern hair loss: a retrospective cohort study. Skin Appendage Disorders. 2024;10(4):293–300.
• Price VH et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology. 2000.
• Yang X, Qiao R, Cheng W, et al. Comparative efficacy of 2% minoxidil alone against combination of 2% minoxidil and low-level laser therapy in female pattern hair loss: a randomized controlled trial in Chinese females. Photodiagnosis and Photodynamic Therapy. 2024;45:103966.
• Finasteride and depression: regulatory failure. Journal of Public Health. 2026 (online 15 Oct). PubMed 42878119

Explore Theradome laser hair growth helmets